Trials / Terminated
TerminatedNCT01011686
Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence
A Phase I Clinical Study of ANT-SM (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Fecal Incontinence to Evaluate Safety
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Anterogen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. There's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ANT-SM is autologous adipose-derived stem cell, and so, expect of no immune responses. In this study, patients are given injection of ANT-AM in anal sphincter and followed for 4 weeks to test the safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ANT-SM | autologous adipose-derived stem cell |
Timeline
- First posted
- 2009-11-11
- Last updated
- 2011-03-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01011686. Inclusion in this directory is not an endorsement.